ロード中...
ADME of Antibody–Maytansinoid Conjugates
The concept of treating cancer with antibody-drug conjugates (ADCs) has gained momentum with the favorable activity and safety of trastuzumab emtansine (T-DM1), SAR3419, and lorvotuzumab mertansine (IMGN901). All three ADCs utilize maytansinoid cell-killing agents which target tubulin and suppress m...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer US
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3475867/ https://ncbi.nlm.nih.gov/pubmed/22875610 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1208/s12248-012-9386-x |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|